Research
Hormonal
Gamma-linolenic acid (GLA) improves nerve conduction velocity in diabetic patients, leading to improved blood flow and reduced tingling in extremities.
If you have diabetes and experience tingling in your hands or feet, GLA supplements might help improve nerve function and blood flow, potentially reducing these symptoms. It is a supportive measure for managing diabetic neuropathy.
ModerateSupportsMEDIUM confidence
GLA also improves nerve conduction velocity in diabetic patients [23,24], leading to improved blood flow and reduced tingling of extremities.
Why this rating
Cites clinical studies, but the paper is a review and does not provide detailed statistical outcomes.
Source
Gamma Linolenic Acid: An Antiinflammatory Omega-6 Fatty Acid
Rakesh Kapoor et al. · Current Pharmaceutical Biotechnology · 2006
DOI 10.2174/138920106779116874
narrative_reviewCited 354×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Gamma-linolenic acid (GLA) supplementation reduces inflammation and joint symptoms in rheumatoid arthritis patients, acting as an NSAID-sparing agent by producing anti-inflammatory prostaglandins (PGE1) and leukotrienes (LTB4 inhibition).Moderate
- Gamma-linolenic acid (GLA) improves the efficacy and reduces the side effects of tamoxifen in breast cancer patients, including improving transcutaneous absorption.Moderate
- Gamma-linolenic acid (GLA) exhibits tumoricidal activity against various cancers (breast, pancreas, colon, brain) and inhibits metastasis by downregulating osteonectin and stimulating metastasis suppressor genes.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →